Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.76 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114487 | 0.90 | PPARG (0.87) | PPARGFABP4FABP5 | |
| SCHEMBL5120195 | 0.89 | PPARG (0.86) | PPARG | |
| SCHEMBL5112392 | 0.89 | PPARG (0.83) | PPARGSLC22A12FABP4FABP5 | |
| SCHEMBL5113706 | 0.89 | PPARG (0.87) | PPARG | |
| SCHEMBL5112208 | 0.88 | PPARG (0.76) | PPARGMEN1KMT2A | |
| SCHEMBL5112256 | 0.87 | PPARG (0.79) | PPARG | |
| SCHEMBL5119547 | 0.86 | PPARG (0.81) | PPARGMEN1KMT2A | |
| SCHEMBL5113561 | 0.86 | PPARG (1.00) | PPARG | |
| SCHEMBL5234837 | 0.85 | PPARG (0.90) | PPARG | |
| SCHEMBL5114191 | 0.85 | PPARG (0.88) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885SLC22A12 1651/4885LMNA 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.